|
Name |
Leucylproline
|
Molecular Formula | C11H20N2O3 | |
IUPAC Name* |
(2S)-1-[(2S)-2-amino-4-methylpentanoyl]pyrrolidine-2-carboxylic acid
|
|
SMILES |
CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N
|
|
InChI |
InChI=1S/C11H20N2O3/c1-7(2)6-8(12)10(14)13-5-3-4-9(13)11(15)16/h7-9H,3-6,12H2,1-2H3,(H,15,16)/t8-,9-/m0/s1
|
|
InChIKey |
VTJUNIYRYIAIHF-IUCAKERBSA-N
|
|
Synonyms |
Leucylproline; l-leucyl-l-proline; Leu-pro; 6403-35-6; CHEMBL189210; CHEBI:73580; (2S)-1-[(2S)-2-amino-4-methylpentanoyl]pyrrolidine-2-carboxylic acid; leucyl-proline; H-Leu-Pro-OH; L-Leu-L-Pro; L-Leu-L-Pro-OH; starbld0035034; L-Proline, 1-L-leucyl-; SCHEMBL3052903; DTXSID30214012; LP; ZINC4556774; BDBM50169151; AKOS010419273; Q27141752; (S)-1-((S)-2-Amino-4-methyl-pentanoyl)-pyrrolidine-2-carboxylic acid; L-P
|
|
CAS | 6403-35-6 | |
PubChem CID | 80817 | |
ChEMBL ID | CHEMBL189210 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 228.29 | ALogp: | -1.8 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.6 | Aromatic Rings: | 1 |
Heavy Atoms: | 16 | QED Weighted: | 0.746 |
Caco-2 Permeability: | -5.904 | MDCK Permeability: | 0.00332309 |
Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.005 |
Human Intestinal Absorption (HIA): | 0.054 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.002 |
Blood-Brain-Barrier Penetration (BBB): | 0.688 | Plasma Protein Binding (PPB): | 8.35% |
Volume Distribution (VD): | 0.406 | Fu: | 87.88% |
CYP1A2-inhibitor: | 0.018 | CYP1A2-substrate: | 0.058 |
CYP2C19-inhibitor: | 0.059 | CYP2C19-substrate: | 0.123 |
CYP2C9-inhibitor: | 0.012 | CYP2C9-substrate: | 0.666 |
CYP2D6-inhibitor: | 0.07 | CYP2D6-substrate: | 0.198 |
CYP3A4-inhibitor: | 0.015 | CYP3A4-substrate: | 0.061 |
Clearance (CL): | 9.462 | Half-life (T1/2): | 0.793 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.636 |
Drug-inuced Liver Injury (DILI): | 0.099 | AMES Toxicity: | 0.004 |
Rat Oral Acute Toxicity: | 0.036 | Maximum Recommended Daily Dose: | 0.029 |
Skin Sensitization: | 0.172 | Carcinogencity: | 0.019 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.027 |
Respiratory Toxicity: | 0.119 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001093 | 0.680 | D0I0EG | 0.612 | ||||
ENC000918 | 0.533 | D0N5HJ | 0.388 | ||||
ENC001906 | 0.508 | D00SEB | 0.376 | ||||
ENC000810 | 0.438 | D07HGR | 0.323 | ||||
ENC002451 | 0.351 | D0X5SJ | 0.322 | ||||
ENC002115 | 0.333 | D00WUF | 0.296 | ||||
ENC001902 | 0.310 | D03KYG | 0.284 | ||||
ENC001215 | 0.288 | D08BTB | 0.264 | ||||
ENC001303 | 0.281 | D0N4EC | 0.258 | ||||
ENC005708 | 0.277 | D01STB | 0.248 |